GlaxoSmithKline expects its performance in China to take a hit from Beijing's probe into bribery allegedly carried out by senior staff, the British drugs firm said Wednesday, and described the matter as "shameful".
A sign outside GlaxoSmithKline's offices in Shanghai, pictured on July 1, 2013. GlaxoSmithKline expects its financial performance in China to take a hit from Bejing's probe into bribery allegedly carried out by senior staff, the British pharmaceuticals company said on Wednesday.
"Clearly, we are likely to see some impact to our performance in China as a result of the current investigation, but it is too early to quantify the extent of this," GSK chief executive Andrew Witty said in a results statement.
This article is older than 60 days, which we reserve for our premium members only.You can subscribe to our premium member subscription, here.